The DTC Telehealth Brand Unit Economics Model, Built From First Principles

A direct-to-consumer telehealth brand looks like a healthcare company and behaves like a subscription business. The product economics are excellent — compounded medications carry high gross margins — but the thing that decides whether the brand makes money is not the margin on any single order. It is the relationship between what you pay to acquire a patient and how much gross profit that patient generates before they churn. Model that relationship correctly and the rest is execution.

This is a first-principles unit-economics walkthrough for operators, not investment advice. It builds the model one line at a time: gross margin per order, contribution margin per month, lifetime value across retained months, and the LTV:CAC ratio that ties it together. The deeper clinic-level view is in the full clinic unit-economics breakdown; here we build the brand model from scratch.

---

What Is the Core Unit of a DTC Telehealth Brand?

The core unit is a retained patient, not a shipped order. A single order is high-margin but small; the economics only work when you count the stream of refills a patient generates over their tenure. That reframing — from transaction to subscription — is the whole game, because it moves the analysis from "what do I make on this box" to "what is a patient worth, and what did they cost."

Everything downstream follows from three numbers per patient: the contribution margin they generate each month, the number of months they stay, and the cost to acquire them. The first two multiply into lifetime value; the third is CAC. A brand that knows these three numbers by category can make every other decision — how much to spend on ads, which categories to push, when to worry about churn — with confidence. A brand that does not is guessing. The benchmark ranges for these inputs are collected in CAC and LTV benchmarks for 2026.

---

How Much Gross Margin Does a Single Order Produce?

Commonly 60-80 percent, because the per-unit cost to compound and ship a dose is low against the cash price a patient pays for convenient, recurring access. Public comparables anchor the range — Hims and Hers has reported company-wide gross margins around 74-79 percent in its investor financials. But gross margin is only the first line; the honest figure is contribution margin, which nets out the other real per-order costs.

Here is a representative single-order breakdown. The numbers are illustrative — your pharmacy pricing and cash price will differ — but the shape is the point:

Line item	Illustrative amount	Notes
Patient cash price (monthly)	$199	Recurring subscription price
Pharmacy compounding + dispensing	$35	Low per-unit compounding cost
Shipping / cold chain	$18	Higher for injectables
Provider approval	$15	Licensed provider review
Flat fulfillment fee	$5	Decoupled from drug value
Contribution margin	$126	~63% of cash price

That $126 is the monthly building block of lifetime value. Note that the pharmacy line is not the largest non-price cost — provider time and shipping matter, and a flat fulfillment fee keeps the calculation clean. The mechanics of where this margin originates are in where the compounded-medication margin comes from.

---

How Do You Turn Monthly Margin Into Lifetime Value?

Multiply the monthly contribution margin by the number of months a patient stays. If a patient nets $126 per month and remains for 10 months, gross lifetime value is about $1,260. Change the retention assumption and the whole model moves — which is why retention, not drug cost, is the variable that most rewards attention.

Retention is also where subscription design pays off. Auto-refill, adherence support, and a frictionless reorder experience extend tenure, and each additional retained month is nearly pure contribution margin because acquisition was already paid once. The compounding effect is dramatic: doubling average tenure roughly doubles LTV without changing CAC at all. This is the argument, in numbers, for building the clinic around retention rather than one-off sales — expanded in how subscription refills compound revenue.

---

What Does CAC Do to the Model?

CAC sets the bar the LTV has to clear, and it varies enormously by category. Acquisition is cheap in some verticals and expensive in others, which means the same LTV can be a great business or a bad one depending on what you paid to start it. Representative ranges operators use as planning anchors:

Category	Typical CAC range	Character
Sexual health	$70-140	Efficient acquisition, strong intent
Hair loss	$100-200	Low cost, high retention
Weight management	$150-300	High demand, competitive auction
TRT / men's hormones	$180-300	Higher CAC, high LTV and retention

Put CAC next to LTV and the business reveals itself. A TRT patient at $250 CAC and a $126 monthly contribution recovers acquisition in about two months and, at 10 months' tenure, returns roughly 5:1 on LTV:CAC — a strong business. The same margin against a $600 CAC in an over-auctioned category is a much harder one. The category-by-category benchmarks live in CAC and LTV benchmarks for 2026.

---

What Ratio Makes the Business Work?

Target LTV:CAC of 3:1 or better, with CAC payback inside a few months. Three dollars of lifetime gross profit per dollar of acquisition cost is the widely used threshold for a fundable, self-sustaining DTC business; below it, growth and overhead are hard to fund, and far above it you may be under-spending on acquisition and leaving growth on the table.

Two disciplines keep the ratio honest. First, use gross-profit LTV, not revenue LTV — a ratio built on revenue flatters a business that has thin margins, and telehealth's margins are good precisely because you should measure them properly. Second, watch payback alongside the ratio: a 4:1 LTV:CAC that takes 18 months to recover CAC will strangle cash flow as you scale, while a 3:1 that pays back in three months compounds cleanly. The two levers you actually pull are retention (extends LTV) and acquisition efficiency (lowers CAC); drug cost, being already low, is rarely worth optimizing. The broader margin context is in telehealth gross-margin benchmarks.

---

Key Takeaways

• The core unit is a retained patient; the P&L is won on lifetime value, not single-order margin.
• Gross margin per compounded order is commonly 60-80 percent; contribution margin after provider and fulfillment costs is the number to build on.
• LTV is monthly contribution margin times retained months — retention moves the model more than any other input.
• CAC varies sharply by category, from roughly $70-140 in sexual health to $180-300 in TRT, and sets the payback bar.
• Target LTV:CAC of 3:1 or better on a gross-profit basis, with CAC payback inside a few months.
• Keep fulfillment fees flat and fair-market to stay predictable and compliant; the levers that matter are retention and acquisition efficiency.

---

Frequently Asked Questions

What is a good LTV:CAC ratio for a telehealth brand?

The widely used benchmark is 3:1 or better — three dollars of lifetime gross profit per dollar of acquisition cost. Below roughly 3:1 the business struggles to fund growth; well above it you may be underinvesting in acquisition. Just as important is CAC payback: recovering acquisition cost within a few months keeps cash flow healthy as you scale.

How do I calculate lifetime value for a compounded-medication subscription?

Multiply monthly contribution margin per patient by expected retained months. Contribution margin is cash price minus pharmacy cost, shipping, provider approval, and flat fulfillment fees. If a patient nets $120 per month and stays 10 months, gross LTV is about $1,200. Retention assumptions drive the number more than any single-order figure, so model them conservatively.

Why is CAC, not drug cost, the real constraint?

Because compounded-medication gross margins are structurally high — the low per-unit cost leaves a wide spread. The binding constraint is what you pay to acquire a patient and how long they stay. A brand can post 80 percent gross margin and still lose money by overpaying for patients who churn before payback. The model lives or dies on CAC and retention.

How should platform and fulfillment fees appear in the model?

As flat, fair-market per-order or per-seat costs, decoupled from the medication's price. That keeps the model predictable and compliant: percentage-of-drug-value markups or pharmacy take-rates create anti-kickback and EKRA exposure. In the table, a flat fulfillment fee sits alongside pharmacy cost and shipping as a known line item, so contribution margin per order stays clean.

---

neolife is the fulfillment rail priced as a flat, fair-market per-order fee — a predictable line in your model rather than a cut of your margin — sitting on top of the pharmacy you already use. If you want unit economics you can actually forecast and a pharmacy relationship that stays yours, talk to us. This post is educational and not financial or legal advice; model your own numbers.